Bafna Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was ₹1.54.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹6.18.
During the past 12 months, the average EBIT per Share Growth Rate of Bafna Pharmaceuticals was 56.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -6.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bafna Pharmaceuticals's EBIT per Share or its related term are showing as below:
NSE:BAFNAPH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -17.9 Med: 7.9 Max: 46.1
Current: -6.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bafna Pharmaceuticals was 46.10% per year. The lowest was -17.90% per year. And the median was 7.90% per year.
NSE:BAFNAPH's 3-Year EBIT Growth Rate is ranked worse than 72.01% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs NSE:BAFNAPH: -6.50
Bafna Pharmaceuticals (NSE:BAFNAPH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bafna Pharmaceuticals EBIT per Share Related Terms
Bafna Pharmaceuticals EBIT per Share Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a EBIT per Share of ₹6.18 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bafna Pharmaceuticals and its competitors. According to the industry distribution chart, Bafna Pharmaceuticals ranks #584 out of 811 companies in the Drug Manufacturers industry, placing it in the top 72%.
Is Bafna Pharmaceuticals' EBIT per Share too high?
Bafna Pharmaceuticals' current EBIT per Share is ₹6.18. Based on the distribution chart, Bafna Pharmaceuticals ranks #584 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #584 out of 811 companies for EBIT per Share. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current EBIT per Share is ₹6.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.72, compared to a current price of ₹216.45 — trading 138.6% above its estimated fair value. The current EBIT per Share is ₹6.18. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current EBIT per Share is ₹6.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹216.45 is trading 138.6% above its estimated GF Value™ of ₹90.72.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
EBIT per Share: ₹6.18
GF Value™: ₹90.72 vs. price of ₹216.45 (138.6% above fair value)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
